EXE vs. RIGL
EXE (Expand Energy Corp) and RIGL (Rigel Pharmaceuticals, Inc.) are both stocks. EXE operates in Oil & Gas E&P (Energy), while RIGL operates in Biotechnology (Healthcare). Over the past 5 years, EXE returned 14.81%/yr vs -3.96%/yr for RIGL. At a 0.09 correlation, their price movements are largely independent.
Performance
EXE vs. RIGL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, EXE achieves a -18.63% return, which is significantly higher than RIGL's -23.30% return.
EXE
- 1D
- 1.95%
- 1M
- -6.62%
- YTD
- -18.63%
- 6M
- -20.38%
- 1Y
- -20.29%
- 3Y*
- 6.27%
- 5Y*
- 14.81%
- 10Y*
- —
RIGL
- 1D
- 2.40%
- 1M
- 2.24%
- YTD
- -23.30%
- 6M
- -19.45%
- 1Y
- 54.23%
- 3Y*
- 27.10%
- 5Y*
- -3.96%
- 10Y*
- 3.28%
EXE vs. RIGL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
EXE Expand Energy Corp | -18.63% | 14.35% | 33.18% | -14.77% | 62.34% | 53.16% |
RIGL Rigel Pharmaceuticals, Inc. | -23.30% | 154.64% | 16.00% | -3.33% | -43.40% | -44.79% |
Correlation
The correlation between EXE and RIGL is -0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.05 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (All Time) Calculated using the full available price history since Feb 10, 2021 | 0.09 |
The correlation between EXE and RIGL shifts across timeframes, from -0.08 (1 year) to 0.09 (all time), reflecting how their relationship changes across market environments.
Fundamentals
EXE:
$21.37M
RIGL:
$646.69M
EXE:
$17.89
RIGL:
$19.21
EXE:
4.96
RIGL:
1.71
EXE:
1.14
RIGL:
2.08
EXE:
0.00
RIGL:
1.62
EXE:
$14.10B
RIGL:
$299.77M
EXE:
$8.89B
RIGL:
$279.95M
EXE:
$7.00B
RIGL:
$125.80M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
EXE vs. RIGL — Risk / Return Rank
EXE
RIGL
EXE vs. RIGL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Expand Energy Corp (EXE) and Rigel Pharmaceuticals, Inc. (RIGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EXE | RIGL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.42 | ||
| Sortino ratioReturn per unit of downside risk | -2.42 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.20 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | -0.72 | 1.09 | -1.81 |
| Martin ratioReturn relative to average drawdown | -1.31 | 1.91 | -3.22 |
Loading charts...
Drawdowns
EXE vs. RIGL - Drawdown Comparison
The maximum EXE drawdown since its inception was -29.69%, smaller than the maximum RIGL drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for EXE and RIGL.
Loading charts...
Drawdown Indicators
| EXE | RIGL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -29.69% | -99.37% | +69.68% |
Max Drawdown (1Y)Largest decline over 1 year | -28.32% | -50.08% | +21.76% |
Max Drawdown (3Y)Largest decline over 3 years | -28.32% | -57.75% | +29.43% |
Max Drawdown (5Y)Largest decline over 5 years | -29.69% | -85.24% | +55.55% |
Max Drawdown (10Y)Largest decline over 10 years | — | -86.40% | — |
Current DrawdownCurrent decline from peak | -26.92% | -96.93% | +70.01% |
Average DrawdownAverage peak-to-trough decline | -10.98% | -90.91% | +79.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.50% | 28.64% | -13.14% |
Volatility
EXE vs. RIGL - Volatility Comparison
The current volatility for Expand Energy Corp (EXE) is 7.74%, while Rigel Pharmaceuticals, Inc. (RIGL) has a volatility of 12.05%. This indicates that EXE experiences smaller price fluctuations and is considered to be less risky than RIGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| EXE | RIGL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.74% | 12.05% | -4.31% |
Volatility (6M)Calculated over the trailing 6-month period | 22.57% | 36.64% | -14.07% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.76% | 69.89% | -38.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 35.13% | 85.46% | -50.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.78% | 82.81% | -48.03% |
Dividends
EXE vs. RIGL - Dividend Comparison
EXE's dividend yield for the trailing twelve months is around 3.59%, while RIGL has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
EXE Expand Energy Corp | 3.59% | 2.89% | 2.45% | 4.70% | 10.16% | 1.74% |
RIGL Rigel Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
EXE vs. RIGL - Financials Comparison
This section allows you to compare key financial metrics between Expand Energy Corp and Rigel Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EXE vs. RIGL - Profitability Comparison
EXE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Expand Energy Corp reported a gross profit of 3.71B and revenue of 4.40B. Therefore, the gross margin over that period was 84.3%.
RIGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.
EXE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Expand Energy Corp reported an operating income of 1.53B and revenue of 4.40B, resulting in an operating margin of 34.8%.
RIGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.
EXE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Expand Energy Corp reported a net income of 1.16B and revenue of 4.40B, resulting in a net margin of 26.4%.
RIGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.
Frequently Asked Questions
EXE and RIGL have a correlation of -0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RIGL has higher volatility (12.05%) compared to EXE (7.74%). In terms of maximum drawdown, EXE dropped -29.69% vs RIGL's -99.37%.
RIGL currently has the higher Sharpe Ratio (0.78 vs -0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for EXE and RIGL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer